Methods for inducing sustained immune response
AssigneeTNI Biotech, Inc.
InventorNicholas P. Plotnikoff
Life of this patent
Estimating the term…
Abstract
A method for promoting a sustained increased level of T-cell production in immunocompromised subjects in which method enkephalin peptides are administered according to an intermittent dose schedule. In particular, the method involves treatment of immunocompromised patients which includes the administration of enkephalin, either alone or in conjunction with other therapies, in an initial dosage regimen, with periodic booster dosages of enkephalin as necessary to maintain sustained immune system response.
Claims16
A method for promoting a sustained increased level of T-cell production in immunocompromised subjects in which method enkephalin peptides are administered according to an intermittent dose schedule.
A method of treatment of immunocompromised patients which includes the administration of enkephalin, either alone or in conjunction with other therapies, in an initial dosage regimen, with periodic booster dosages of enkephalin as necessary to maintain sustained immune system response.
A method of treatment of cancer by administering enkephalin peptides according to an intermittent dose schedule.
A method of treatment of cancer which includes the administration of enkephalin, either alone or in conjunction with other therapies, in an initial dosage regimen, with periodic booster dosages of enkephalin as necessary to maintain sustained immune system response.
A method of treating cortisol-induced immunosuppression in a subject by treating said subject with an initial dosage regimen of enkephalin peptides followed by periodic booster dosages of enkephalin peptides.
A method of inhibiting cortisol-induced suppression of cytokine production in a subject by treating said subject with an initial dosage regimen of enkephalin peptides followed by periodic booster dosages of enkephalin peptides.
A method of inhibiting a cortisol-induced reduction of gene transcription of IL2 in a subject by treating said subject with an initial dosage regimen of enkephalin peptides followed by periodic booster dosages of enkephalin peptides.
A method of inhibiting cortisol-induced down-regulation of cytotoxic cells or NK lymphocytes in a subject by treating said subject with an initial dosage regimen of enkephalin peptides followed by periodic booster dosages of enkephalin peptides.
Dependencies are inferred from the claim text.